Toll Free: 1-888-928-9744

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 71 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016', provides in depth analysis on Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted pipeline therapeutics. 

The report provides comprehensive information on the Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) 
- The report reviews Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Overview 6 Therapeutics Development 7 Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Products under Development by Stage of Development 7 Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Products under Development by Therapy Area 8 Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Products under Development by Indication 9 Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Products under Development by Companies 13 Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Therapeutics Assessment 17 Assessment by Monotherapy/Combination Products 17 Assessment by Mechanism of Action 18 Assessment by Route of Administration 19 Assessment by Molecule Type 21 Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Companies Involved in Therapeutics Development 22 Karyopharm Therapeutics, Inc. 22 Stemline Therapeutics, Inc. 24 Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Drug Profiles 25 KPT-251 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 KPT-276 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 KPT-350 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 KPT-8602 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 selinexor - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 SL-801 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 verdinexor - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Dormant Projects 51 Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Discontinued Products 54 Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Featured News & Press Releases 55 Jul 27, 2016: Karyopharm to Present Updated Phase 2 Clinical Data from SIGN Study at European Society of Medical Oncology 2016 Annual Meeting 55 Jul 27, 2016: Karyopharms Selinexor First-in-Human Phase 1 Clinical Trial Data Published in Journal of Clinical Oncology 56 Jun 16, 2016: Karyopharm Outlines Key Selinexor Clinical Development Achievements 57 Jun 10, 2016: Karyopharm Presents Preliminary STOMP Phase 1b Clinical Data at 2016 European Hematology Association Annual Meeting 58 Jun 10, 2016: Karyopharm Therapeutics Presents data on KPT-8602 at 2016 European Hematology Association Annual Meeting 59 Jun 06, 2016: Moffitt researchers present phase 1 study results of selinexor combination therapy; multiple myeloma 60 May 19, 2016: Karyopharm to Present Preliminary STOMP Phase 1B Clinical Data at 2016 European Hematology Association Annual Meeting 60 May 18, 2016: Karyopharm to Present Selinexor Clinical Data at the American Society of Clinical Oncology Annual Meeting 61 May 03, 2016: Stemline Therapeutics Clears First Cohort of Patients in Ongoing SL-801 Phase 1 Trial 63 Apr 20, 2016: Karyopharm Presents Data Demonstrating the Potential of Nuclear Export Protein Exportin 1 (XPO1) Inhibition in the Treatment of Traumatic Brain Injury 63 Mar 31, 2016: Karyopharm Receives NIAID Grant to Advance Development of KPT-350 for the Treatment of Lupus 64 Mar 16, 2016: Karyopharm to Present Data on Oncology drug Selinexor (KPT-330) at the 2016 American Association for Cancer Research Annual Meeting 65 Mar 16, 2016: Karyopharm to Present Data on Oncology drug KPT-8602 at the 2016 American Association for Cancer Research Annual Meeting 67 Mar 04, 2016: Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published in Journal of Clinical Oncology 68 Jan 19, 2016: Karyopharm Initiates Second Generation SINE Compound Clinical Trial in Multiple Myeloma 69 Appendix 70 Methodology 70 Coverage 70 Secondary Research 70 Primary Research 70 Expert Panel Validation 70 Contact Us 70 Disclaimer 71
List of Tables
Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 9 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Early Stage Products, H2 2016 12 Number of Products under Development by Companies, H2 2016 13 Products under Development by Companies, H2 2016 14 Products under Development by Companies, H2 2016 (Contd..1) 15 Products under Development by Companies, H2 2016 (Contd..2) 16 Assessment by Monotherapy/Combination Products, H2 2016 17 Number of Products by Stage and Mechanism of Action, H2 2016 18 Number of Products by Stage and Route of Administration, H2 2016 20 Number of Products by Stage and Molecule Type, H2 2016 21 Pipeline by Karyopharm Therapeutics, Inc., H2 2016 22 Pipeline by Stemline Therapeutics, Inc., H2 2016 24 Dormant Projects, H2 2016 51 Dormant Projects (Contd..1), H2 2016 52 Dormant Projects (Contd..2), H2 2016 53 Discontinued Products, H2 2016 54



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $3500
Multi User - US $7000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify